# Ofatumumab for Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

> **NCT01113632** · PHASE2 · COMPLETED · sponsor: **SCRI Development Innovations, LLC** · enrollment: 77 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma

## Interventions

- **DRUG:** Ofatumumab

## Key facts

- **NCT ID:** NCT01113632
- **Lead sponsor:** SCRI Development Innovations, LLC
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07
- **Primary completion:** 2015-03
- **Final completion:** 2016-08
- **Target enrollment:** 77 (ACTUAL)
- **Last updated:** 2016-09-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01113632

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01113632, "Ofatumumab for Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01113632. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*